Search This Blog

Friday, June 11, 2021

Bristol Myerrs, Acceleron: Phase 2 Study of Reblozyl in Beta Thalassemia

 Results showed treatment with Reblozyl plus best supportive care improved anemia in 77% of patients compared to placebo

Reblozyl was generally well tolerated and improvements in hemoglobin correlated with improved patient-reported outcomes over a continuous 12-week interval

In the study, 89.6% of patients treated with Reblozyl remained transfusion free vs. 67.3% of patients in the placebo arm at weeks 1-24

Results featured in Presidential Symposium of European Hematology Association’s Virtual Congress as one of top six abstracts submitted

https://www.businesswire.com/news/home/20210611005039/en/Bristol-Myers-Squibb-and-Acceleron-Present-First-Results-from-Phase-2-BEYOND-Study-of-Reblozyl%C2%AE-luspatercept-aamt-in-Adults-with-Non-Transfusion-Dependent-NTD-Beta-Thalassemia

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.